» Insights into real-world data in advanced HCC

In this video update, HCC CONNECT expert Prof. Matthias Pinter reviews recent real-world data (RWD) discussed in advanced HCC.

He discusses real-world efficacy and safety of systemic therapies, treatment patterns in real-world clinical practice, and RWD on systemic therapy in patient populations excluded from Phase 3 RCT (Child-Pugh class B and with a history of liver transplantation).

Clinical takeaways:

Although RWD cannot substitute controlled randomised clinical trials, RWD addresses questions not sufficiently answered by clinical trial data
RWD can provide insights into the performance and outcomes of new anticancer therapies in routine clinical practice, information on patients underrepresented in clinical trials and captures less common and delayed adverse events

Dr Matthias Pinter works at the Medical University of Vienna in Austria where he also received both his MD and PhD. He is board-certified for Internal Medicine and Gastroenterology and Hepatology. Since 2017, he has led the hepatocellular carcinoma programme and research group at the Division of Gastroenterology and Hepatology at the Medical University of Vienna. His main research interests include the systemic treatment of liver cancer, particularly the identification of prognostic markers and scores that may help to identify patients most likely to benefit from specific therapies. To broaden his knowledge and expertise in basic research and experimental oncology, he worked as a research fellow and postdoc at renowned institutions, including the University of Bern in Switzerland and the Massachusetts General Hospital/Harvard Medical School in the United States. He has published numerous original papers and review articles on liver cancer in prestigious peer-reviewed journals covering the categories oncology, gastroenterology and hepatology, and radiology.

Assoc. Prof. Matthias Pinter has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, BMS, Ipsen, Eisai, Lilly, MSD and Roche.